Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
2016 Standout
Alteration of enzyme specificity by computational loop remodeling and design
2009 StandoutNobel
Bifluoride Ion Mediated SuFEx Trifluoromethylation of Sulfonyl Fluorides and Iminosulfur Oxydifluorides
2019 StandoutNobel
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials
2004
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma
2002
EGFR Antagonists in Cancer Treatment
2008 Standout
Capecitabine can induce acute coronary syndrome similar to5-fluorouracil
2002
New advances in antibiotic development and discovery
2005
β-lactams against methicillin-resistant
2005
Capecitabine: a novel agent for the treatment of solid tumors
2001
Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent
2015
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Capecitabine
2001
Contribution of platelets to tumour metastasis
2011 Standout
Isavuconazonium: First Global Approval
2015
Natural products: A continuing source of novel drug leads
2013 Standout
A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia
2007
The dual role of thymidine phosphorylase in cancer development and chemotherapy
2009
Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases
2014
New and emerging treatments for fungal infections
2007
Cancer drug resistance: an evolving paradigm
2013 Standout
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
Cephalosporins in clinical development
2004
Waves of resistance: Staphylococcus aureus in the antibiotic era
2009 Standout
Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
2004 Standout
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
2008 Standout
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
2010 Standout
Isavuconazole: A Comprehensive Review of Spectrum of Activity of a New Triazole
2010
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature
2005
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer
2003
Current Options in Antifungal Pharmacotherapy
2008
Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America
2006 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Capecitabine
2003
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug
1999
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients
2001
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Capecitabine: A review
2005
Novel β-lactam antibiotics and inhibitor combinations
2008
Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections
2012
Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors
2013
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Predictors of Mortality for Methicillin-Resistant Staphylococcus aureus Health-Care–Associated Pneumonia
2006
Natural products to drugs: natural product derived compounds in clinical trials
2005
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
2010 Standout
Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections
2013
Discovery and resupply of pharmacologically active plant-derived natural products: A review
2015 Standout
Natural products in drug discovery
2008 Standout
Depression and anxiety in women with early breast cancer: five year observational cohort study
2005 Standout
Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations
2011
Removal of cytostatic drugs from aquatic environment: A review
2013 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida , Aspergillus , Fusarium , and Scedosporium Species
2008
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment
2009 Standout
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
5-Fluorouracil Incorporated into DNA Is Excised by the Smug1 DNA Glycosylase to Reduce Drug Cytotoxicity
2007 StandoutNobel
Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study
2001
Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
2001
Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review
2002
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children
2011 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Investigational treatments for postoperative surgical site infections
2007
Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates
2015
Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA β-lactam to demonstrate clinical efficacy
2007
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial
2007
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
2015 Standout
Isavuconazole (BAL4815) Pharmacodynamic Target Determination in an In Vivo Murine Model of Invasive Pulmonary Aspergillosis against Wild-Type and cyp51 Mutant Isolates of Aspergillus fumigatus
2013
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
Three Decades of β-Lactamase Inhibitors
2010 Standout
Ceftobiprole: An Extended-Spectrum Anti–Methicillin-Resistant Staphylococcus aureus Cephalosporin
2008
Structural and Biochemical Studies of a Fluoroacetyl-CoA-Specific Thioesterase Reveal a Molecular Basis for Fluorine Selectivity
2010 StandoutNobel
Phase I/II Trial of Capecitabine, Oxaliplatin, and Radiation for Rectal Cancer
2003
Ceftobiprole: drug evaluation and place in therapy
2019
2015 ESC Guidelines for the management of infective endocarditis
2015 Standout
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
2018 Standout
Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results
2002
The Traditional Medicine and Modern Medicine from Natural Products
2016 Standout
Isavuconazole: A New and Promising Antifungal Triazole for the Treatment of Invasive Fungal Infections
2008
Catalytic Asymmetric Protonation of Silyl Ketene Imines
2013 StandoutNobel
Drug Resistance in Cancer: An Overview
2014 Standout
Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda®) for locally advanced and/or metastatic breast cancer
2004
Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy
2004
In Vitro Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds
2013
Antimicrobial Resistance in ESKAPE Pathogens
2020 Standout
Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy
2004
Works of Brigitte Roos being referenced
Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients
1999
Effect of Mild and Moderate Liver Disease on the Pharmacokinetics of Isavuconazole after Intravenous and Oral Administration of a Single Dose of the Prodrug BAL8557
2009
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.
1999
Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
1998
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
2000
Multiple-Dose Pharmacokinetics and Safety of the New Antifungal Triazole BAL4815 after Intravenous Infusion and Oral Administration of Its Prodrug, BAL8557, in Healthy Volunteers
2005
P987 Steady-state bioavailability of oral isavuconazole in healthy volunteers
2007
P1675 QTc measurements during a placebo- and actively controlled multiple dose study of two different dosing regimens of isavuconazole
2007
Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers
2005
Multiple-Dose Pharmacokinetics and Safety of a Novel Broad-Spectrum Cephalosporin (BAL5788) in Healthy Volunteers
2004
Single-Dose Pharmacokinetics and Safety of a Novel Broad-Spectrum Cephalosporin (BAL5788) in Healthy Volunteers
2004